Q2 Earnings Forecast for CorMedix Issued By Leerink Partnrs

CorMedix Inc. (NASDAQ:CRMD - Free Report) - Stock analysts at Leerink Partnrs upped their Q2 2025 EPS estimates for CorMedix in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings of $0.14 per share for the quarter, up from their prior estimate of $0.05. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix's Q4 2025 earnings at $0.12 EPS, FY2026 earnings at $2.03 EPS, FY2027 earnings at $2.65 EPS and FY2028 earnings at $3.13 EPS.

CorMedix (NASDAQ:CRMD - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.05. The firm had revenue of $39.08 million for the quarter, compared to the consensus estimate of $38.90 million. During the same quarter last year, the firm posted ($0.25) earnings per share.

A number of other equities research analysts also recently weighed in on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $12.00 target price on shares of CorMedix in a report on Wednesday, March 26th. Needham & Company LLC lifted their price objective on shares of CorMedix from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday, May 7th. D. Boral Capital reissued a "buy" rating and set a $15.00 target price on shares of CorMedix in a research note on Tuesday, May 6th. Leerink Partners initiated coverage on shares of CorMedix in a research note on Friday, March 7th. They issued an "outperform" rating and a $18.00 price target for the company. Finally, StockNews.com upgraded shares of CorMedix from a "sell" rating to a "hold" rating in a report on Tuesday, April 1st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $15.00.

CorMedix Stock Performance

Shares of NASDAQ CRMD traded down $0.01 during midday trading on Friday, reaching $11.62. The stock had a trading volume of 883,620 shares, compared to its average volume of 1,634,710. The company's 50 day moving average price is $8.81 and its 200 day moving average price is $9.74. CorMedix has a twelve month low of $3.61 and a twelve month high of $13.85. The firm has a market cap of $788.13 million, a price-to-earnings ratio of -14.35 and a beta of 1.54.

Institutional Trading of CorMedix

Hedge funds and other institutional investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. grew its stake in shares of CorMedix by 699.7% during the first quarter. SBI Securities Co. Ltd. now owns 8,685 shares of the company's stock valued at $54,000 after buying an additional 7,599 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in CorMedix in the 4th quarter worth approximately $81,000. Essex Financial Services Inc. bought a new stake in CorMedix in the first quarter valued at approximately $63,000. EntryPoint Capital LLC purchased a new stake in shares of CorMedix during the first quarter valued at approximately $66,000. Finally, Captrust Financial Advisors bought a new position in shares of CorMedix in the fourth quarter worth approximately $90,000. Hedge funds and other institutional investors own 34.18% of the company's stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.